• Completed dosing of all ADOA patients in Phase 1 SAD study of PYC-001
• Presented safety and early efficacy data, including no serious adverse events and encouraging trend towards improved visual acuity
• Progressing PYC-001 into a global Phase 1/2 MAD study in Q4 2025

PYC Therapeutics announced that it has completed dosing of all ADOA patients in the Phase 1 Single Ascending Dose (SAD) study of its drug candidate PYC-001, which is designed to address the underlying cause of the blinding eye disease Autosomal Dominant Optic Atrophy (ADOA). The company will present safety and early efficacy data from this SAD study at the Neuro-Ophthalmology Society of Australia (NOSA) conference in Auckland, New Zealand between 11-13 September 2025. The presentation will highlight the safety and tolerability profile of PYC-001, with no treatment-emergent serious adverse events observed in any patient dosed with the drug candidate to date. Additionally, an encouraging early trend of improvement in measures of visual acuity in the treated-eye of patients enrolled in the SAD study will also be presented. PYC is now preparing to progress PYC-001 into a global Multiple Ascending Dose (MAD) study in ADOA patients, with the objective of establishing clinical proof-of-concept prior to progression into a global registrational trial. The global Phase 1/2 MAD study is expected to commence in Q4 of 2025.

PYC is now preparing to progress PYC-001 into a global Phase 1/2 Multiple Ascending Dose (MAD) study in ADOA patients, with the objective of establishing clinical proof-of-concept prior to progression into a global registrational trial.